Research context
A GHRH analogue with specific approved clinical use in some jurisdictions.
Regulatory note: Verify local laws, product approval and professional guidance before any human use. This profile is not a recommendation for use.
GHRH medicine
Tesamorelin
A GHRH analogue with specific approved clinical use in some jurisdictions.
55 connected records46 graded citations0 external identifiers
Evidence map
Claims linked to original records.
Evidence levels describe study design. They do not by themselves establish safety or effectiveness.
Ditta AM, Naeem RM, Sami MM, Abdul Rafey M, Ali H, Amjad MW, Jahangir F, Rizvi KA, Mohammad F, Abu Dawood H, Suleman M, Saddique MN
Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.
pubmed
Erlandson KM, Gustafson L, Johnson JE, Kulik GL, Khuu V, Chahal N, Walpert AR, Galdamez ME, Zorgno I, Foldyna B, Jarraya M, Reusch JE, Lee H, Grinspoon SK, Jankowski CM, Fourman LT
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
pubmed
Stewart CE, French KP, Wright TJ, Wilhoit K, Randolph KM, Danesi CP, Gilkison CR, Karmonik C, Lu L, Dillon EL, Durham WJ, Urban RJ, Sheffield-Moore M, Masel BE
The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.
pubmed 2026
Villegas Meza AD, Nocek M, Mitchell BC, Lizarraga M, DeFoor MT, Ruzbarsky JJ, Huard J, Philippon MJ
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
pubmed
Beach R, Tims-Cook Z, McGary CS, Thote T
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.
pubmed
Renke G, Chinellato L
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
pubmed
Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
pubmed 2026
Chege BM, Mwangi PW, Githinji CG, Bukachi F
Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model.
pubmed 2026
Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M · Frontiers in endocrinology
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
pmc 2026
The aim of this study is to test whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, will significantly improve memory and thinking in HIV.
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
clinicaltrials 2015
Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure. Growth hormone is a hormone produced in the pituitary gland that helps regulate metabolism and...
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
clinicaltrials 2017
This study is examining the effects of growth hormone releasing hormone (GHRH) on mild cognitive impairment (MCI). GHRH will be given at a dose of 1mg/day for 10 weeks to subjects with MCI as well as healthy controls.
The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment
clinicaltrials 2015
HIV-infection and its treatment are often associated with an increase in belly fat, as well as abnormal cholesterol and problems metabolizing sugar. People with HIV infection and increased belly fat often have decreased growth hormone (GH) levels. Low GH levels may contribute independently to increased...
Effects of Growth Hormone Releasing Hormone in HIV
clinicaltrials 2010
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of tesamorelin therapy of patients with...
Body Composition and Adipose Tissue in HIV
clinicaltrials 2017
This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease. Participants receive tesamorelin or matching placebo for 52 weeks, with standardized lifestyle counseling in both groups. Liver fat is...
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
clinicaltrials 2026
Sleep-disordered breathing is characterized primarily by partial or total upper airway obstruction during sleep. The most common form of sleep-disordered breathing is obstructive sleep apnea (OSA) due to recurrent collapse of the upper airway with the onset of sleep state. The major risk factors associated...
Egrifta Replacement and Sleep Disordered Breathing
clinicaltrials 2013
Obesity is strongly associated with risk of cardiovascular disease (CVD). Data increasingly suggest that visceral adipose tissue (VAT) accumulation -- or increased abdominal fat -- is particularly deleterious to cardiovascular health, but further study is needed to test this idea. Increased abdominal fat may also...
Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue
clinicaltrials 2012
To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and Type 2 diabetes mellitus (T2DM).
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
clinicaltrials 2012
The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries. The investigators hypothesize that treatment with tesamorelin will result in faster and more substantial recovery of motor and sensory function following surgical repair of injured...
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
clinicaltrials 2017
Liver disease is one of the leading co-morbidities of human immunodeficiency virus (HIV) infection, and nonalcoholic fatty liver disease (NAFLD) is present in approximately 30-40% of patients with HIV infection. Nonalcoholic steatohepatitis (NASH) is a more severe form of NAFLD in which increased liver fat...
Tesamorelin Effects on Liver Fat and Histology in HIV
clinicaltrials 2014
The purpose of this trial is to examine the short-term effects of Growth Hormone Releasing Hormone (GHRH, tesamorelin) administration in healthy men. We hypothesize that GHRH will increase GH pulse height and will not affect insulin sensitivity.
Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men
clinicaltrials 2009
The purpose of this study was to determine whether TH9507, a stabilized analogue of growth hormone-releasing factor (GRF), would have an effect on insulin sensitivity or control of diabetes in patients with type 2 diabetes.
Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
clinicaltrials 2010
Ditta AM, Naeem RM, Sami MM, Abdul Rafey M, Ali H, Amjad MW, Jahangir F, Rizvi KA, Mohammad F, Abu Dawood H, Suleman M, Saddique MN · Journal of the International Association of Providers of AIDS Care
Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.
pmc
Erlandson KM, Gustafson L, Johnson JE, Kulik GL, Khuu V, Chahal N, Walpert AR, Galdamez ME, Zorgno I, Foldyna B, Jarraya M, Reusch JE, Lee H, Grinspoon SK, Jankowski CM, Fourman LT · BMJ open
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
pmc
Stewart CE, French KP, Wright TJ, Wilhoit K, Randolph KM, Danesi CP, Gilkison CR, Karmonik C, Lu L, Dillon EL, Durham WJ, Urban RJ, Sheffield-Moore M, Masel BE · eNeurologicalSci
The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.
pmc 2026
Gattu AK, Fourman LT · Current opinion in HIV and AIDS
Metabolic dysfunction-associated steatotic liver disease in people with HIV.
pmc
Chege BM, Mwangi PW, Githinji CG, Bukachi F · Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model.
pmc 2026
Arora G, Conde KR, Desouza CV · Journal of clinical medicine
Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss.
pmc
Caldji C, Marsolais C, Sicard E, de Chantal M, Anstett K · Open Forum Infectious Diseases
P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants.
pmc 2026
&NA; · Springer Science and Business Media LLC
Tesamorelin promising for HIV-associated lipodystrophy
crossref 2007
&NA; · Springer Science and Business Media LLC
Tesamorelin fighting fat
crossref 2008
&NA; · Springer Science and Business Media LLC
Tesamorelin trims less than taut tummies
crossref 2009
&NA; · Springer Science and Business Media LLC
Tesamorelin rounds on HIV-associated lipodystrophy
crossref 2008
Sohita Dhillon · Springer Science and Business Media LLC
Spotlight on Tesamorelin in HIV-Associated Lipodystrophy†
crossref 2011
Andy McLarnon · Springer Science and Business Media LLC
Tesamorelin can improve cognitive function
crossref 2012
Roger Bedimo · Informa UK Limited
Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
crossref 2011
Carl Grunfeld, Argyris Dritselis, Peter Kirkpatrick · Springer Science and Business Media LLC
Tesamorelin
crossref 2011
Sohita Dhillon · Springer Science and Business Media LLC
Tesamorelin
crossref 2011
Takara Leah Stanley, Meghan N. Feldpausch, Jin-Hee Oh, Karen L. Branch, Hang Lee, Martin Torriani et al. · JAMA · 87 citations
Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation
openalex 2014
Takara Leah Stanley, Lindsay T. Fourman, Meghan N. Feldpausch, Julia Purdy, Isabel Zheng, Chelsea S. Pan et al. · The Lancet HIV · 85 citations
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
openalex 2019
Sohita Dhillon · Drugs · 24 citations
Tesamorelin
openalex 2011
Carl Grünfeld, Argyris Dritselis, Peter N. Kirkpatrick · Nature Reviews Drug Discovery · 18 citations
Tesamorelin
openalex 2011
Julian Falutz, Soraya Allas, Jean‐Claude Mamputu, Diane Potvin, Donald P. Kotler, Michael S. Somero et al. · AIDS · 65 citations
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
openalex 2008
Julian Falutz, Diane Potvin, Jean‐Claude Mamputu, Hani Assaad, Monika Zoltowska, Sophie‐Élise Michaud et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 77 citations
Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension
openalex 2010
Julian Falutz, Jean‐Claude Mamputu, Diane Potvin, Graeme J Moyle, Graziella Soulban, Helen C. Loughrey et al. · The Journal of Clinical Endocrinology & Metabolism · 99 citations
Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data
openalex 2010
Lindsay T. Fourman, James M. Billingsley, George Agyapong, Shannan J. Ho Sui, Meghan N. Feldpausch, Julia Purdy et al. · JCI Insight · 26 citations
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
openalex 2020
Connected data hub
Records with source provenance.
Reviewed records carry an admin-reviewed badge. Automated records link back to the provider for independent checking.
Regulatory Label
2 recordsopenfdaAdmin reviewed
EGRIFTA SV — Dosage and Administration
2 DOSAGE AND ADMINISTRATION The recommendations in this prescribing information only apply to EGRIFTA SV (tesamorelin) for injection 2 mg per vial formulation. For recommendations for tesamorelin for injection 1 mg per vial formulation, see the EGRIFTA prescribing...
openfdaAdmin reviewed
EGRIFTA WR — Dosage and Administration
2 DOSAGE AND ADMINISTRATION The recommendations in this prescribing information only apply to EGRIFTA WR (tesamorelin) for injection 11.6 mg per vial formulation. For recommendations for tesamorelin for injection 2 mg per vial formulation, see the EGRIFTA SV...
Clinical Trial
20 recordsclinicaltrialsAdmin reviewed
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease. Participants receive tesamorelin or matching placebo for 52 weeks, with standardized lifestyle...
clinicaltrialsAdmin reviewed
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
People with HIV experience earlier impairments in physical function compared to people in the general population. They also exhibit an earlier presentation and more rapid development of frailty, a multisystemic syndrome of aging characterized by reduced activity, fatigue,...
clinicaltrialsAdmin reviewed
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure. Growth hormone is a hormone produced in the...
clinicaltrialsAdmin reviewed
Body Composition and Adipose Tissue in HIV
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective...
clinicaltrialsAdmin reviewed
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries. The investigators hypothesize that treatment with tesamorelin will result in faster and more substantial recovery of motor and...
clinicaltrialsAdmin reviewed
Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia
Background: People who have had a traumatic brain injury (TBI) often have trouble sleeping. TBI may also alter hormones, which can cause poor sleep. Researchers believe that a form of growth hormone releasing hormone (GHRH) might improve sleep...
clinicaltrialsAdmin reviewed
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
The aim of this study is to test whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, will significantly improve memory and thinking in HIV.
clinicaltrialsAdmin reviewed
Tesamorelin Effects on Liver Fat and Histology in HIV
Liver disease is one of the leading co-morbidities of human immunodeficiency virus (HIV) infection, and nonalcoholic fatty liver disease (NAFLD) is present in approximately 30-40% of patients with HIV infection. Nonalcoholic steatohepatitis (NASH) is a more severe form...
clinicaltrialsAdmin reviewed
Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients
The primary objective of the study is to determine the PK (tesamorelin) and PD (IGF-1) profiles of tesamorelin after a single 2 mg subcutaneous administration and after repeated administration once daily for 14 consecutive days. Secondary objectives include...
clinicaltrialsAdmin reviewed
Egrifta Replacement and Sleep Disordered Breathing
Sleep-disordered breathing is characterized primarily by partial or total upper airway obstruction during sleep. The most common form of sleep-disordered breathing is obstructive sleep apnea (OSA) due to recurrent collapse of the upper airway with the onset of...
clinicaltrialsAdmin reviewed
Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue
Obesity is strongly associated with risk of cardiovascular disease (CVD). Data increasingly suggest that visceral adipose tissue (VAT) accumulation -- or increased abdominal fat -- is particularly deleterious to cardiovascular health, but further study is needed to test...
clinicaltrialsAdmin reviewed
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and Type 2 diabetes mellitus (T2DM).
clinicaltrialsAdmin reviewed
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
The purpose of this observational, 10-year, prospective cohort study is to assess the potential safety concerns of long-term exposure to EGRIFTA® in HIV-infected subjects with abdominal lipohypertrophy compared with a similar group of subjects not exposed to EGRIFTA®.
clinicaltrialsAdmin reviewed
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
A significant proportion of COPD subjects experience muscle wasting, which has been associated with increased morbidity, impaired physical functioning, and a poor quality of life. Muscle wasting is associated with reduced muscle strength in COPD subjects. In particular,...
clinicaltrialsAdmin reviewed
Effects of Growth Hormone Releasing Hormone in HIV
HIV-infection and its treatment are often associated with an increase in belly fat, as well as abnormal cholesterol and problems metabolizing sugar. People with HIV infection and increased belly fat often have decreased growth hormone (GH) levels. Low...
clinicaltrialsAdmin reviewed
Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men
The purpose of this trial is to examine the short-term effects of Growth Hormone Releasing Hormone (GHRH, tesamorelin) administration in healthy men. We hypothesize that GHRH will increase GH pulse height and will not affect insulin sensitivity.
clinicaltrialsAdmin reviewed
Effects of Short-term Growth Hormone in HIV-infected Patients
The purpose of this study is to examine the short-term effects of two different doses of growth hormone, compared to treatment with growth hormone releasing hormone, on the brain's secretion of growth hormone and the body's glucose metabolism....
clinicaltrialsAdmin reviewed
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation
clinicaltrialsAutomated import
The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment
This study is examining the effects of growth hormone releasing hormone (GHRH) on mild cognitive impairment (MCI). GHRH will be given at a dose of 1mg/day for 10 weeks to subjects with MCI as well as healthy controls.
clinicaltrialsAutomated import
Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
The purpose of this study was to determine whether TH9507, a stabilized analogue of growth hormone-releasing factor (GRF), would have an effect on insulin sensitivity or control of diabetes in patients with type 2 diabetes.
Open Access Article
8 recordspmcAutomated import
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M · Frontiers in endocrinology
pmcAutomated import
Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model.
Chege BM, Mwangi PW, Githinji CG, Bukachi F · Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
pmcAutomated import
The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.
Stewart CE, French KP, Wright TJ, Wilhoit K, Randolph KM, Danesi CP, Gilkison CR, Karmonik C, Lu L, Dillon EL, Durham WJ, Urban RJ, Sheffield-Moore M, Masel BE · eNeurologicalSci
pmcAutomated import
P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants.
Caldji C, Marsolais C, Sicard E, de Chantal M, Anstett K · Open Forum Infectious Diseases
pmcAutomated import
Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.
Ditta AM, Naeem RM, Sami MM, Abdul Rafey M, Ali H, Amjad MW, Jahangir F, Rizvi KA, Mohammad F, Abu Dawood H, Suleman M, Saddique MN · Journal of the International Association of Providers of AIDS Care
pmcAutomated import
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
Erlandson KM, Gustafson L, Johnson JE, Kulik GL, Khuu V, Chahal N, Walpert AR, Galdamez ME, Zorgno I, Foldyna B, Jarraya M, Reusch JE, Lee H, Grinspoon SK, Jankowski CM, Fourman LT · BMJ open
pmcAutomated import
Metabolic dysfunction-associated steatotic liver disease in people with HIV.
Gattu AK, Fourman LT · Current opinion in HIV and AIDS
pmcAutomated import
Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss.
Arora G, Conde KR, Desouza CV · Journal of clinical medicine
Publication
8 recordspubmedAutomated import
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M
pubmedAutomated import
Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model.
Chege BM, Mwangi PW, Githinji CG, Bukachi F
pubmedAutomated import
The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.
Stewart CE, French KP, Wright TJ, Wilhoit K, Randolph KM, Danesi CP, Gilkison CR, Karmonik C, Lu L, Dillon EL, Durham WJ, Urban RJ, Sheffield-Moore M, Masel BE
pubmedAutomated import
Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.
Ditta AM, Naeem RM, Sami MM, Abdul Rafey M, Ali H, Amjad MW, Jahangir F, Rizvi KA, Mohammad F, Abu Dawood H, Suleman M, Saddique MN
pubmedAutomated import
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
Erlandson KM, Gustafson L, Johnson JE, Kulik GL, Khuu V, Chahal N, Walpert AR, Galdamez ME, Zorgno I, Foldyna B, Jarraya M, Reusch JE, Lee H, Grinspoon SK, Jankowski CM, Fourman LT
pubmedAutomated import
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
Villegas Meza AD, Nocek M, Mitchell BC, Lizarraga M, DeFoor MT, Ruzbarsky JJ, Huard J, Philippon MJ
pubmedAutomated import
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.
Beach R, Tims-Cook Z, McGary CS, Thote T
pubmedAutomated import
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
Renke G, Chinellato L
Article
8 recordsopenalexAutomated import
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
Lindsay T. Fourman, James M. Billingsley, George Agyapong, Shannan J. Ho Sui, Meghan N. Feldpausch, Julia Purdy et al. · JCI Insight · 26 citations
openalexAutomated import
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
Takara Leah Stanley, Lindsay T. Fourman, Meghan N. Feldpausch, Julia Purdy, Isabel Zheng, Chelsea S. Pan et al. · The Lancet HIV · 85 citations
openalexAutomated import
Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation
Takara Leah Stanley, Meghan N. Feldpausch, Jin-Hee Oh, Karen L. Branch, Hang Lee, Martin Torriani et al. · JAMA · 87 citations
openalexAutomated import
Tesamorelin
Sohita Dhillon · Drugs · 24 citations
openalexAutomated import
Tesamorelin
Carl Grünfeld, Argyris Dritselis, Peter N. Kirkpatrick · Nature Reviews Drug Discovery · 18 citations
openalexAutomated import
Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data
Julian Falutz, Jean‐Claude Mamputu, Diane Potvin, Graeme J Moyle, Graziella Soulban, Helen C. Loughrey et al. · The Journal of Clinical Endocrinology & Metabolism · 99 citations
openalexAutomated import
Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension
Julian Falutz, Diane Potvin, Jean‐Claude Mamputu, Hani Assaad, Monika Zoltowska, Sophie‐Élise Michaud et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 77 citations
openalexAutomated import
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
Julian Falutz, Soraya Allas, Jean‐Claude Mamputu, Diane Potvin, Donald P. Kotler, Michael S. Somero et al. · AIDS · 65 citations
Scholarly Work
9 recordscrossrefAutomated import
Tesamorelin can improve cognitive function
Andy McLarnon · Springer Science and Business Media LLC
crossrefAutomated import
Spotlight on Tesamorelin in HIV-Associated Lipodystrophy†
Sohita Dhillon · Springer Science and Business Media LLC
crossrefAutomated import
Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
Roger Bedimo · Informa UK Limited
crossrefAutomated import
Tesamorelin
Sohita Dhillon · Springer Science and Business Media LLC
crossrefAutomated import
Tesamorelin
Carl Grunfeld, Argyris Dritselis, Peter Kirkpatrick · Springer Science and Business Media LLC
crossrefAutomated import
Tesamorelin trims less than taut tummies
&NA; · Springer Science and Business Media LLC
crossrefAutomated import
Tesamorelin rounds on HIV-associated lipodystrophy
&NA; · Springer Science and Business Media LLC
crossrefAutomated import
Tesamorelin fighting fat
&NA; · Springer Science and Business Media LLC
crossrefAutomated import
Tesamorelin promising for HIV-associated lipodystrophy
&NA; · Springer Science and Business Media LLC
Live discovery
Latest research signals
Live results from PubMed, ClinicalTrials.gov and UniProt. These may not yet have been reviewed or stored in the Data Hub.
Recent PubMed records
Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review.PMID 42862021 · 2026 Sep 30Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.PMID 42538058 · 2026 Jan-DecTesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.PMID 42419889 · 2026 Jul 8The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.PMID 42395176 · 2026The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.PMID 42382101 · 2026 SepRegistered clinical studies
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected PersonsNCT02572323 · COMPLETEDTesamorelin to Improve Functional Outcomes After Peripheral Nerve InjuryNCT03150511 · RECRUITINGSMART: Somatotrophics, Memory, and Aging Research TrialNCT00257712 · COMPLETEDReviewed UniProt records
Responsible use of information
Fitzbio provides educational and research reference material. It does not diagnose, prescribe or replace advice from a qualified healthcare professional.